Bayer Aktiengesellschaft (BAYN.DE)

27,19 -0,12 (-0,46 %) À partir de 04:35PM CEST. Marché ouvert.

Bayer Aktiengesellschaft

Kaiser-Wilhelm-Allee 1
Leverkusen 51368
Germany
49 214 30 1
https://www.bayer.com

Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - General
Employés à temps plein: 96 931

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. William N. Anderson	Chairman of the Management Board & CEO	8,43M	S.O.	1966
Mr. Wolfgang U. Nickl	CFO & Member of Management Board	1,98M	S.O.	1969
Mr. Heiko W. J. Schipper	Member of Management Board & President of the Consumer Health Division	1,95M	S.O.	1969
Mr. Stefan Oelrich	Head of the Pharmaceuticals Division & Member of the Board of Management	1,95M	S.O.	1968
Mr. Rodrigo Santos	Member of Management Board & President of the Crop Science Division	2,17M	S.O.	1973
Ms. Heike Prinz	Chief Talent Officer, Labor Director & Member of Management Board	1,33M	S.O.	1964
Mr. Julio Triana	Member of Management Board & President of Consumer Health Division	S.O.	S.O.	1966
Dr. Sebastian Guth Ph.D.	Chief Operating Officer	S.O.	S.O.	S.O.
Dr. Jost Reinhard	Head of Investor Relations	S.O.	S.O.	1972
Mr. Michael Preuss	Head of Communications, Government Relations and Corporate Brand	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en EUR.

Description

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. The Crop Science segment offers seeds, improved plant traits, innovative chemical and biological crop protection products, digital solutions, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Bayer Aktiengesellschaft en date du 1 avril 2024 est 3. Les scores principaux sont Audit : 10; Société : 2; Droits des actionnaires : 1; Compensation : 2.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.